AXL - A New Player in Resistance to HER2 Blockade
Source : https://pubmed.ncbi.nlm.nih.gov/37864955/
HER2 is a driver in solid tumors, mainly breast, oesophageal and gastric cancer, through activation of oncogenic signaling pathways such as PI3K or MAPK. HER2 overexpression associates with aggressive disease...
Preclinical studies show that AXL drives anti-HER2 resistance and metastasis through dimerization with HER2 and activation of downstream pathways in breast cancer. Moreover, AXL inhibition restores response to HER2 blockade in vitro and in vivo.
-
Albert Dekker2yrthis is not new but not clear how management may be changed
Detection of Early Myocardial Dysfunction by Imaging Biomarkers in Cancer Patients Undergoing Photon Beam vs. Proton Beam Radiotherapy: A Prospective Study
Source : https://www.mdpi.com/2308-3425/10/10/418
1. Background: We sought to determine acute and subacute changes in cardiac function after proton beam (PBT) and photon beam (PhT) radiotherapy (RT) using conventional and two-dimensional speckle tracking echocardiography...
Patients who underwent PhT but not PBT had reduced tissue Doppler velocities and SRe values during follow-up, suggesting early myocardial relaxation abnormalities. PBT shows promise as a cardiac-sparing RT technology.
-
Albert Dekker2yrnot clear how that will work in the real life
Abemaciclib as adjuvant treatment for high-risk early breast cancer
Source : https://www.sciencedirect.com/science/article/pii/S1130634323003367?via=ihub
Adaptar el informe GHEMA de abemaciclib, un inhibidor de quinasas dependientes de ciclinas 4 y 6, con autorización de la Agencia Europea del Medicamen...
The selection of a pharmacological alternative must be supported by criteria of scientific evidence and efficiency. The evaluation and selection of drugs, carried out according to their therapeutic value and incremental clinical benefit, allows their positioning in the therapeutic care guidelines and protocols so that patients receive the...
Evidence into practice: a national cohort study of NICE-recommended oncological drug therapy utilisation among women diagnosed with invasive breast cancer in England - British Journal of Cancer
Source : https://www.nature.com/articles/s41416-023-02439-z
Multiple drug treatments are approved for invasive breast cancer (IBC). We investigated uptake of NICE-recommended oncological drugs and variation by age, comorbidity burden and geographical region. Women (aged 50+ years)...
Use of NICE-recommended drugs for IBC in routine care is variable, with lowest use among women aged 70+ years. Improving access to effective treatments is an important step in improving outcomes.
Small-molecule inhibitors of kinases in breast cancer therapy: recent advances, opportunities, and challenges
Source : https://www.frontiersin.org/articles/10.3389/fphar.2023.1244597/full
Breast cancer is the most common malignancy in women worldwide and despite significant advancements in detection, treatment, and management of cancer, it is still the leading cause of malignancy related...
Relevance: Breast cancer is the most common malignancy in women worldwide and despite significant advancements in detection, treatment, and management of cancer, it is still the leading cause of malignancy related deaths in women. Understanding the fundamental biology of breast cancer and creating fresh diagnostic and therapeutic strategies...